References
- Miyamoto S. Allergic disease. [English translation] Jpn J Guth Exp Med. 2002;79:189–192.
- Matsumoto I, Odashima H, Nishima M, et al. The changes in allergic disease during fifteen years. [English translation] Jpn J Allerg. 1999;48: 435–442.
- Hosoi S, Asai K, Ozaki M. The investigation of allergic epidemiology in Kyoto. [English translation] Jpn J Allerg. 1997;46: 1025–1035.
- Ikeda H, Sato E, Kitaura T, et al. Daily cost of ophthalmic solutions for treating glaucoma in Japan. Jpn J Ophthalmol. 2001;45: 99–102.
- Stewart WC, Hudgins AC, Pruitt CA, Sine C. Daily cost of newer glaucoma agents. J Ocul Pharmacol Ther. 1999;15:379–388.
- Fiscella RG, Geller JL, Gryz LL, et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128: 426–433.
- Mick AB, Gonzalez S, Dunbar MT, McSoley JJ. A cost analysis of the prostaglandin analogs. Optometry. 2002;73:614–619.
- Stewart WC, Sine C, Cate E, et al. Daily cost of beta-adrenergic blocker therapy. Arch Ophthalmol. 1997;115:853–856.
- Ikeda H, Kadoyama M, Miyake K, et al. Pharmaceutical properties of ophthalmic solutions for rational use: total number of drops in one bottle, volume of one drop, osmotic ratio and pH. [English translation] Jpn J Hosp Pharm. 1998;24: 595–600.
- Ikeda H, Toyomi A, Miyake K, et al. Pharmaceutical properties of ophthalmic preparations marketed as over-the-counter drugs: osmotic ratio, pH, total number of drops and volume of a drop. [English translation] Atarashii Ganka. 1999; 16:249–252.
- Kitano S, Kogure F, Miyanaga Y, et al. Clinical evaluation of KC-404 ophthalmic solution in treatment of allergic conjunctivitis (including pollinosis) and vernal conjunctivitis. — A comparative study with disodium cromoglycate ophthalmic solution. [English translation] Atarashii Ganka. 1999;16: 1449–1465.
- Sawa M, Masuda K, Kitano S, et al. Clinical evaluation of R50547 ophthalmic suspension in allergic conjunctivitis and in pollinosis conjunctivitis. — Single-masked comparative study with disodium cromoglycate ophthalmic solution. [English translation] Atarashii Ganka. 1995;12: 333–350.
- Manabe M, Masuda H, Sakuragi S, et al. Clinical effect of 0.25% AA-673 ophthalmic solution on allergic and pollinosis conjunctivitis. — A comparative clinical study using disodium cromoglycate ophthalmic solution as a control. Folia Ophthalmol Jpn. 1987;38: 1108–1119.
- Sawa M, Masuda K, Usui M, Komemushi S. Efficacy of 0.1% bromfenac sodium ophthalmic solution for ocular surface inflammation. — A double-masked controlled trial. Folia Ophthalmol Jpn. 1997;48:717–724.
- Montoro JB, Lalueza P, Cano SM, et al. Drop size and systemic adverse effects in timolol ophthalmic solution. Ann Pharmacother. 1990;24:439–440.
- Belanger J, Winstead R. Eyedrop comparison. Am Pharm. 1992;32: 463.
- Ball SF, Schneider E. Cost of p-adrenergic receptor blocking agent for ocular hypertension. Arch Ophthalmol. 1002;110:654–657.
- Edward PA, Akaho E, Fujii M. Japanese pharmacy: innovation mixed with tradition. Ann Pharmacother. 1995;29:181–185.
- Haicl P, Cerna H. Allergodil eye drops in the treatment of allergic conjunctivitis. Cesk Slov Oftalmol. 2002;58: 254–258.